← back to search

Todd Hembrough

Durham VA Medical Center · US
Area of research
Cancer Research · Pulmonary and Respiratory Medicine
Research interest
Research interests include Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, and Cancer, Hypoxia, and Metabolism.
h-index
31
citations
4,576
works
250
NIH funding
primary concept
email

Recent publications

Targeting Aggressive B-cell Lymphomas through Pharmacological Activation of the Mitochondrial Protease OMA1
Molecular Cancer Therapeutics 2023cited by 14position: middledoi
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade
Cancer Discovery 2020cited by 333position: middledoi
<i>MET</i> Exon 14–altered Lung Cancers and MET Inhibitor Resistance
Clinical Cancer Research 2020cited by 78position: middledoi
Ado-Trastuzumab Emtansine for Patients With <i>HER2</i>-Mutant Lung Cancers: Results From a Phase II Basket Trial
Journal of Clinical Oncology 2018cited by 555position: middledoi
Targeting wild-type KRAS-amplified gastroesophageal cancer through combined MEK and SHP2 inhibition
Nature Medicine 2018cited by 273position: middledoi
<i>EGFR</i> and <i>MET</i> Amplifications Determine Response to HER2 Inhibition in <i>ERBB2</i> -Amplified Esophagogastric Cancer
Cancer Discovery 2018cited by 145position: middledoi
Targeted Therapies for Targeted Populations: Anti-EGFR Treatment for <i>EGFR</i> -Amplified Gastroesophageal Adenocarcinoma
Cancer Discovery 2018cited by 119position: middledoi
Targeted data-independent acquisition for mass spectrometric detection of RAS mutations in formalin-fixed, paraffin-embedded tumor biopsies
Journal of Proteomics 2018cited by 33position: lastdoi
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS
Nature 2017cited by 560position: middledoi
An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Nature Medicine 2017cited by 179position: middledoi
Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment
Annals of Oncology 2016cited by 55position: middledoi
MET tyrosine kinase receptor expression and amplification as prognostic biomarkers of survival in gastroesophageal adenocarcinoma
Cancer 2016cited by 44position: middledoi
Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH
Gastric Cancer 2015cited by 44position: lastdoi
Absolute Quantitation of Met Using Mass Spectrometry for Clinical Application: Assay Precision, Stability, and Correlation with MET Gene Amplification in FFPE Tumor Tissue
PLoS ONE 2014cited by 54position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Daniel V.T. Catenacci · University of Chicago5 papers (2014–2018)Shu‐Yuan Xiao · Kunming Medical University3 papers (2014–2018)Emily O’Day · Framingham State University3 papers (2015–2018)John Hart · United Continental (United States)3 papers (2014–2018) · 3 papers (2014–2016) · 3 papers (2014–2016)Bob T. Li · Presbyterian Hospital3 papers (2017–2020)Charles M. Rudin · New York Proton Center2 papers (2018–2020)Yung‐Jue Bang · Seoul National University2 papers (2015–2016)Adele Blackler · Center for Cancer Research2 papers (2015–2016)Maria E. Arcila · Molecular Oncology (United States)2 papers (2018–2020) · 2 papers (2014–2015)Neal Rosen · Memorial Sloan Kettering Cancer Center2 papers (2017–2017)Alexander Drilon · Université Grenoble Alpes2 papers (2018–2020) · 2 papers (2014–2015)Peng Xu · Ministry of Public Security of the People's Republic of China2 papers (2014–2015)Les Henderson · University of Wisconsin–Madison2 papers (2014–2015)David B. Solit · New York Oncology Hematology2 papers (2017–2018)Ronglai Shen · Memorial Sloan Kettering Cancer Center2 papers (2018–2020)Sarit Schwartz · OncoPlex Diagnostics (United States)2 papers (2017–2018)